Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Chemotherapy

17 evidence topics · 18 sources

Pegylated liposomal doxorubicin in a placebo-controlled phase 3 trial

“In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Seven (14.9%) patients experienced grade 3 or 4 AEs in the PLD group, including neutrophil count decreased (10.6%), mucositis oral (6.4%), white cell decreased (4.3%), and palmar–plantar erythrodysesthesia syndrome (2.1%). No patients reported cardiotoxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“First, the interpretation of our results is limited by a single-center design and relatively small sample size, which had the potential to introduce bias, although these aspects are consistent with other phase III trials in this rare disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Lastly, the current follow-up period may not be sufficient to adequately assess the cardiotoxicity associated with low cumulative doses of PLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote